Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose doctors estimate they have a life expectancy of more than 12 weeks.
• People with a body mass index (a measure of body weight relative to height) between 18 and 32.
• People whose general physical ability and daily functioning falls within a certain range, rated on a standard medical scale (ECOG score of 0 to 2, meaning broadly able to carry out at least some daily activities — confirm with trial site).
• For the first phase of the trial: People with a laboratory-confirmed type of blood cancer called CD20-positive non-Hodgkin's lymphoma, which may include follicular lymphoma (Grades 1–3a), marginal zone lymphoma, small lymphocytic lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma Grade 3b, mantle cell lymphoma, or primary mediastinal large B-cell lymphoma.
• For the second phase of the trial: People with a laboratory-confirmed CD20-positive non-Hodgkin's lymphoma that is a lower-grade type only — specifically follicular lymphoma (Grades 1–3a), marginal zone lymphoma, or small lymphocytic lymphoma.
• People who have at least one measurable area of disease that is at least 1.5 cm at its widest point.
• People who have stopped receiving a specific type of infusion treatment (anti-CD20 therapy) at least 30 days before the planned start of the trial treatment.
• People who are willing and able to provide a tumour tissue sample at the screening stage, if no existing sample is available.
• People with adequate heart function, without serious or uncontrolled heart disease.
• People who meet certain requirements around contraception: including those who are sterile, have a partner who is surgically sterile, are at least 2 years past menopause, or are committed to using an accepted form of birth control throughout the study (and for 3 months after the last dose, for women).

Who may not be able to join:

• People with a known allergy to eggs, or to any ingredient in the trial treatment (CHO-H01).
• People with known or active illnesses — such as poorly controlled autoimmune disease, active infections, or other conditions — that could affect participation or interfere with results.
• People who have previously received certain immunotherapy drugs that work on the PD-L1, PD-1, or CTLA-4 pathways (a type of cancer treatment that affects the immune system — confirm with trial site).
• People who have had an autologous stem cell transplant (using their own stem cells) within the past 100 days, or who have ever had an allogeneic stem cell transplant (using a donor's stem cells).
• People who have a currently detectable hepatitis B surface antigen in their blood, or who have an active hepatitis C infection with detectable virus levels.
• People with a known HIV infection.
• People who have had radiation therapy, a major surgical procedure, or a live vaccine within 28 days before the planned start of treatment.
• People who have had a severe allergic reaction (including anaphylaxis) to mouse-derived proteins, or to a previous infusion of a CD20-targeting antibody treatment.
• People who have been taking, or are currently taking, corticosteroid tablets or injections at a daily dose higher than 15 mg of prednisone (or an equivalent dose of another steroid) within 14 days before the first treatment. Note: steroid creams, inhalers, nasal sprays, and eye drops are generally permitted.
• People whose bone marrow, liver, or kidney function does not meet the required levels (confirm with trial site).
• People with a history of seizure disorder (epilepsy).
• People who are pregnant or breastfeeding.
• For the second phase of the trial only: People for whom a medication called lenalidomide would be medically unsuitable.

Important: Always verify eligibility with the trial site directly before applying.